,address1,address2,city,state,zip,country,phone,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,auditRisk,boardRisk,compensationRisk,shareHolderRightsRisk,overallRisk,governanceEpochDate,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,lastSplitFactor,lastSplitDate,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,debtToEquity,returnOnAssets,returnOnEquity,freeCashflow,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,322 11th Avenue SW,Suite 804,Calgary,AB,T2R 0C5,Canada,403 670 7377,https://www.oncolyticsbiotech.com,Biotechnology,Healthcare,"Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada.",29,"{'maxAge': 1, 'name': 'Dr. Matthew C. Coffey M.B.A., Ph.D.', 'title': 'Pres, CEO & Director', 'fiscalYear': 2022, 'totalPay': 767415, 'exercisedValue': 0, 'unexercisedValue': 0}",6,2,8,3,5,1693526400,1672444800,86400,4,2.19,2.16,2.12,2.1788,2.19,2.16,2.12,2.1788,0.0,1.739151,-6.7187505,277364,277364,1137685,435810,435810,2.1,2.17,900,1400,157742928,1.09,3.39,2.4596,1.86785,0.0,0.0,USD,141852544,0.0,71530043,73368800,1178153,1377481,1689292800,1692057600,0.0163,0.013250001,0.01914,1.45,0.0165,0.338,6.360947,1672444800,1703980800,1688083200,-26840000,-0.32,-0.32,10:95,1527206400,-4.999,NCM,EQUITY,ONCY,ONCY,Oncolytics Biotech Inc.,Oncolytics Biotech Inc.,1002288600,America/New_York,EDT,-14400000,2.15,15.03,4.44,7.38,5.01,1.8,buy,4,24351000,0.336,-28375000,479000,9.239,11.692,2.154,-0.49273,-1.0126001,-16226227,-26480000,0.0,0.0,0.0,CAD,
1,322 11th Avenue SW,Suite 804,Calgary,AB,T2R 0C5,Canada,403 670 7377,https://www.oncolyticsbiotech.com,Biotechnology,Healthcare,"Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada.",29,"{'maxAge': 1, 'name': 'Mr. Kirk J. Look C.A., CA', 'title': 'Chief Financial Officer', 'fiscalYear': 2022, 'totalPay': 542271, 'exercisedValue': 0, 'unexercisedValue': 0}",6,2,8,3,5,1693526400,1672444800,86400,4,2.19,2.16,2.12,2.1788,2.19,2.16,2.12,2.1788,0.0,1.739151,-6.7187505,277364,277364,1137685,435810,435810,2.1,2.17,900,1400,157742928,1.09,3.39,2.4596,1.86785,0.0,0.0,USD,141852544,0.0,71530043,73368800,1178153,1377481,1689292800,1692057600,0.0163,0.013250001,0.01914,1.45,0.0165,0.338,6.360947,1672444800,1703980800,1688083200,-26840000,-0.32,-0.32,10:95,1527206400,-4.999,NCM,EQUITY,ONCY,ONCY,Oncolytics Biotech Inc.,Oncolytics Biotech Inc.,1002288600,America/New_York,EDT,-14400000,2.15,15.03,4.44,7.38,5.01,1.8,buy,4,24351000,0.336,-28375000,479000,9.239,11.692,2.154,-0.49273,-1.0126001,-16226227,-26480000,0.0,0.0,0.0,CAD,
2,322 11th Avenue SW,Suite 804,Calgary,AB,T2R 0C5,Canada,403 670 7377,https://www.oncolyticsbiotech.com,Biotechnology,Healthcare,"Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada.",29,"{'maxAge': 1, 'name': 'Mr. Andrew R. de Guttadauro', 'age': 55, 'title': 'Global Head of Bus. Devel. & Pres of Oncolytics Biotech (U.S.) Inc', 'yearBorn': 1967, 'fiscalYear': 2022, 'totalPay': 464601, 'exercisedValue': 0, 'unexercisedValue': 0}",6,2,8,3,5,1693526400,1672444800,86400,4,2.19,2.16,2.12,2.1788,2.19,2.16,2.12,2.1788,0.0,1.739151,-6.7187505,277364,277364,1137685,435810,435810,2.1,2.17,900,1400,157742928,1.09,3.39,2.4596,1.86785,0.0,0.0,USD,141852544,0.0,71530043,73368800,1178153,1377481,1689292800,1692057600,0.0163,0.013250001,0.01914,1.45,0.0165,0.338,6.360947,1672444800,1703980800,1688083200,-26840000,-0.32,-0.32,10:95,1527206400,-4.999,NCM,EQUITY,ONCY,ONCY,Oncolytics Biotech Inc.,Oncolytics Biotech Inc.,1002288600,America/New_York,EDT,-14400000,2.15,15.03,4.44,7.38,5.01,1.8,buy,4,24351000,0.336,-28375000,479000,9.239,11.692,2.154,-0.49273,-1.0126001,-16226227,-26480000,0.0,0.0,0.0,CAD,
3,322 11th Avenue SW,Suite 804,Calgary,AB,T2R 0C5,Canada,403 670 7377,https://www.oncolyticsbiotech.com,Biotechnology,Healthcare,"Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada.",29,"{'maxAge': 1, 'name': 'Dr. Thomas C. Heineman M.D., Ph.D.', 'title': 'Chief Medical Officer', 'fiscalYear': 2022, 'totalPay': 638762, 'exercisedValue': 0, 'unexercisedValue': 0}",6,2,8,3,5,1693526400,1672444800,86400,4,2.19,2.16,2.12,2.1788,2.19,2.16,2.12,2.1788,0.0,1.739151,-6.7187505,277364,277364,1137685,435810,435810,2.1,2.17,900,1400,157742928,1.09,3.39,2.4596,1.86785,0.0,0.0,USD,141852544,0.0,71530043,73368800,1178153,1377481,1689292800,1692057600,0.0163,0.013250001,0.01914,1.45,0.0165,0.338,6.360947,1672444800,1703980800,1688083200,-26840000,-0.32,-0.32,10:95,1527206400,-4.999,NCM,EQUITY,ONCY,ONCY,Oncolytics Biotech Inc.,Oncolytics Biotech Inc.,1002288600,America/New_York,EDT,-14400000,2.15,15.03,4.44,7.38,5.01,1.8,buy,4,24351000,0.336,-28375000,479000,9.239,11.692,2.154,-0.49273,-1.0126001,-16226227,-26480000,0.0,0.0,0.0,CAD,
4,322 11th Avenue SW,Suite 804,Calgary,AB,T2R 0C5,Canada,403 670 7377,https://www.oncolyticsbiotech.com,Biotechnology,Healthcare,"Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada.",29,"{'maxAge': 1, 'name': 'Ms. Allison  Hagerman P.Eng., P.M.P.', 'title': 'VP of Product Devel.', 'fiscalYear': 2022, 'totalPay': 426112, 'exercisedValue': 0, 'unexercisedValue': 0}",6,2,8,3,5,1693526400,1672444800,86400,4,2.19,2.16,2.12,2.1788,2.19,2.16,2.12,2.1788,0.0,1.739151,-6.7187505,277364,277364,1137685,435810,435810,2.1,2.17,900,1400,157742928,1.09,3.39,2.4596,1.86785,0.0,0.0,USD,141852544,0.0,71530043,73368800,1178153,1377481,1689292800,1692057600,0.0163,0.013250001,0.01914,1.45,0.0165,0.338,6.360947,1672444800,1703980800,1688083200,-26840000,-0.32,-0.32,10:95,1527206400,-4.999,NCM,EQUITY,ONCY,ONCY,Oncolytics Biotech Inc.,Oncolytics Biotech Inc.,1002288600,America/New_York,EDT,-14400000,2.15,15.03,4.44,7.38,5.01,1.8,buy,4,24351000,0.336,-28375000,479000,9.239,11.692,2.154,-0.49273,-1.0126001,-16226227,-26480000,0.0,0.0,0.0,CAD,
5,322 11th Avenue SW,Suite 804,Calgary,AB,T2R 0C5,Canada,403 670 7377,https://www.oncolyticsbiotech.com,Biotechnology,Healthcare,"Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada.",29,"{'maxAge': 1, 'name': 'Jon  Patton', 'title': 'Director of Investor Relations & Communication', 'exercisedValue': 0, 'unexercisedValue': 0}",6,2,8,3,5,1693526400,1672444800,86400,4,2.19,2.16,2.12,2.1788,2.19,2.16,2.12,2.1788,0.0,1.739151,-6.7187505,277364,277364,1137685,435810,435810,2.1,2.17,900,1400,157742928,1.09,3.39,2.4596,1.86785,0.0,0.0,USD,141852544,0.0,71530043,73368800,1178153,1377481,1689292800,1692057600,0.0163,0.013250001,0.01914,1.45,0.0165,0.338,6.360947,1672444800,1703980800,1688083200,-26840000,-0.32,-0.32,10:95,1527206400,-4.999,NCM,EQUITY,ONCY,ONCY,Oncolytics Biotech Inc.,Oncolytics Biotech Inc.,1002288600,America/New_York,EDT,-14400000,2.15,15.03,4.44,7.38,5.01,1.8,buy,4,24351000,0.336,-28375000,479000,9.239,11.692,2.154,-0.49273,-1.0126001,-16226227,-26480000,0.0,0.0,0.0,CAD,
6,322 11th Avenue SW,Suite 804,Calgary,AB,T2R 0C5,Canada,403 670 7377,https://www.oncolyticsbiotech.com,Biotechnology,Healthcare,"Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada.",29,"{'maxAge': 1, 'name': 'Mr. John Mark Lievonen F.C.A., FCA, LLD', 'title': 'Consultant', 'fiscalYear': 2019, 'exercisedValue': 0, 'unexercisedValue': 0}",6,2,8,3,5,1693526400,1672444800,86400,4,2.19,2.16,2.12,2.1788,2.19,2.16,2.12,2.1788,0.0,1.739151,-6.7187505,277364,277364,1137685,435810,435810,2.1,2.17,900,1400,157742928,1.09,3.39,2.4596,1.86785,0.0,0.0,USD,141852544,0.0,71530043,73368800,1178153,1377481,1689292800,1692057600,0.0163,0.013250001,0.01914,1.45,0.0165,0.338,6.360947,1672444800,1703980800,1688083200,-26840000,-0.32,-0.32,10:95,1527206400,-4.999,NCM,EQUITY,ONCY,ONCY,Oncolytics Biotech Inc.,Oncolytics Biotech Inc.,1002288600,America/New_York,EDT,-14400000,2.15,15.03,4.44,7.38,5.01,1.8,buy,4,24351000,0.336,-28375000,479000,9.239,11.692,2.154,-0.49273,-1.0126001,-16226227,-26480000,0.0,0.0,0.0,CAD,
